Acute leukemia M1, or acute myeloid leukemia (M1), generally has a natural course of 2-3 months if the patient does not receive treatment; if treated effectively, there are individual differences in survival. Acute myeloid leukemia M1, also known as acute primitive granulocytic leukemia undifferentiated, means that the patient has more than 90% of primitive granulocytes in the bone marrow. If patients can receive chemotherapy in time and are sensitive to chemotherapeutic drugs, they can usually achieve complete remission within two courses of treatment, and if they can adhere to regular treatment, patients can survive for more than 5 years. If the patient is not sensitive to chemotherapy drugs and cannot achieve complete remission, the prognosis is poor, and the survival period may be only about six months. If the patient achieves complete remission with treatment and actively undergoes hematopoietic stem cell transplantation, he or she can usually survive for a long time, up to several decades. Currently, hematopoietic stem cell transplantation is still an important and effective way to treat acute leukemia, and patients are advised to seek early detection, early diagnosis and early treatment to gain favorable time for treatment.